CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells

Calicheamicin γ ₁ ^I : an Antitumor Antibiotic That Cleaves Double-Stranded DNA Site Specifically

Nada Zein, A M Sinha, William J. McGahren et al. · Science · 1988 · 566 citations

Medicine, Medicinal Chemistry, Pharmacology +13

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

Josée Golay, Manuela Lazzari, Valeria Facchinetti et al. · Blood · 2001 · 421 citations · Full text

Life Sciences, Hematology, Immunology +17

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

John F. DiJoseph, Douglas Armellino, Erwin R. Boghaert et al. · Blood · 2003 · 356 citations · Full text

Medicine, Medicinal Chemistry, Oncology +11

A Green-emitting Fluorescent Protein from Galaxeidae Coral and Its Monomeric Version for Use in Fluorescent Labeling

S. Karasawa, Toshio Araki, Miki Yamamoto‐Hino et al. · Journal of Biological Chemistry · 2003 · 202 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance

Rajat Bannerji, Shinichi Kitada, Ian W. Flinn et al. · Journal of Clinical Oncology · 2003 · 177 citations

Life Sciences, Immunology, Oncology +17